Production of bioactive gastrin from the non-endocrine cell lines CHO and COS-7  by Hayashi, Naoki et al.
ELSEVIER 
FEBS Letters 337 (1994) 27-32 LETTERS 
FEBS 13494 
Production of bioactive gastrin from the non-endocrine cell lines CHO and 
COS-7 
Naoki Hayashi”, Tsuyoshi Kayo”, Kentaro Suganob, Toshiyuki 
aDivision of Molecular Endocrinology, Institute for Endocrinology, Gunma University, Showa-machi, 
‘Health Care Center, University of Tokyo, Tokyo 113, Japan 
Received 26 October 1993; revised version received 24 November 1993 
Takeuchiap* 
Maebashi 371, Japan 
Abstract 
We made a mutated progastrin cDNA construct hat contains a cleavage site (-Arg-4-Arg-‘-Lys -2 -Arg-‘) specific for the Kex2-like endoprotease 
furin, located ahead of the bioactive gastrin. For expressing the mutated progastrin cDNA, we used two non-endocrine cell lines, CHO and COS-7. 
CHO cells exhibit amidating enzyme activity and levels of amidation enzyme mRNA as high as those in the pituitary-derived endocrine cell line GH,, 
whereas COS-7 cells have far less amidating activity and lower amounts of mRNA. Mutant progastrin-expressing CHO cells produced mostly 
amidated gastrin. Gel ~tration showed the size of this gas&in corresponded to that of the synthetic human gas&in-17. In contrast, COS-7 cells 
produced glyc~e~xtended gas&in and only a small amount of amidated gastrin. The difference in the amount of amidated gastrin products produced 
by the two non-endocrine cell lines is due to dieting amounts of the amidation enzyme contained in each cell line. 
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1. Introduction 
Gas&in is a polypeptide hormone with an amide moi- 
ety at its carboxyterminal end, and exhibits a number of 
bioactive forms including gas&in-7 1 (component 1), gas- 
trin-34, gastrin-17, and gas&in-14. This hormone is the 
primary regulator of gastric acid secretion and growth 
of the gastrointestinal mucosa. The amidated gastrin-17 
(Gl7-NH,) is the major molecular form in the antral 
endocrine cells of the stomach, where it is synthesized 
first as a precursor preprogast~n (Fig. la). This precur- 
sor requires a series of post-translational processing re- 
actions to become bioactive gastrin [l]. The processing 
reactions include dibasic cleavage at paired basic resi- 
dues, their subsequent removal by carboxypeptidase H, 
and formation of a carboxyl (C-) terminal amide moiety 
via the action of the a~dation enzyme, ~ptidyl-glycine 
a-amidating mono-oxygenase (PAM). This enzyme reac- 
tion was recently found to be a two-step reaction involv- 
ing the two enzymes peptidyl-glycine a-hydroxylating 
monooxygenase and peptidyl-a-hydroxy-glycine a-ami- 
dating lyase [Z]. In this reaction, the glycine residue at the 
carboxyterminal end serves as the substrate for the ami- 
dation enzymes that leave the amide moiety with the 
gastrin peptide. The amidated gastrin (Gl7-NH2) thus 
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formed, exhibits gastric acid-secreting activity three or- 
ders of magnitude higher than does glycine-extended 
gastrin (Gl7-Gly) [3,4]. 
Non-endocrine cells, including fibroblasts, epithelial 
cells, and hepatocytes produce biologically inactive 
propeptides and convert them to bioactive peptides by 
cleaving a unique consensus sequence -Arg-4-X-3-Lys/ 
Argm2-Arg-’ & X+‘- [5]. This sequence contains an addi- 
tional arginine at position -4 as compared to the com- 
mon cleavage site of most propeptide hormones, -Lys/ 
Argm2-Arg-’ & X+‘-. Proteolytic cleavage of this consen- 
sus sequence is catalyzed by the subtilisin-like endopro- 
tease named furin [6]. Furin is thought to be a mammal- 
ian endoprotease in non-endocrine cells. This endopro- 
tease is present in virtually all non-endocrine cells, in- 
cluding fibroblasts, epithelial cells, and hepatocytes [7]. 
In order to explore the physiolo~cal role of gastrin, 
for example, to make hypergastrinemic animals, or to 
express gastrin in certain local tissues or cells, gastrin 
need to be expressed not only in endocrine cells but also 
in non-endocrine cells. To express gas&in in non-endo- 
crine cells, at least two processing steps need to be over- 
come: cleavage and amidation. The mutated gas&in with 
the concensus cleavage site mentioned above, -Argm4- 
X-3-Lys/Arg-2-Arg-1, should be cleaved in both non- 
endocrine and endocrine cells. Amidation has been 
thought to be a unique function of neuroendocrine cells, 
but this enzyme is dist~buted widely in almost every 
tissue, including exocrine organs and heart [8,9]. Re- 
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cently, Johansen et al. reported the formation of ami- 
dated peptides in a non-endocrine cell line, Chinese ham- 
ster ovary (CHO), by showing the expression of ami- 
dated neuropeptide Y [lo]. Moreover, Eipper et al. dem- 
onstrated the presence of the amidation enzyme mRNA 
in non-endocrine cell lines: Buffalo rat liver BRL 3A 
cells, mouse connective tissue L-M cells, mouse mam- 
mary tumor Cl27 cells, and mouse-embryo-derived fi-
broblast-like NIH3T3 cells [l 11. Thus, it was thought 
possible to generate amidated gastrin from progastrin- 
expressing non-endocrine cells without the co-expression 
of amidation enzyme. 
In this paper, we utilized cells from two contrasting 
non-endocrine cell lines, CHO and the African green 
monkey kidney-derived cell line COS-7. CHO cells con- 
tain substantial amounts of amidation enzyme mRNA 
and its enzyme activity, whereas COS-7 cells have very 
little mRNA, and the enzyme activity is much lower. We 
have constructed an expression vector containing a mu- 
tated gastrin cDNA with the above-stated cleavage site, 
-Arg-4-X-3-Lys/Arg-2-Arg-‘, ahead of the amino termi- 
nus of gastrin- 17. Mutant progastrin-expressing CHO 
cells produced mostly amidated gastrin. In contrast, mu- 
tant progastrin-expressing COS-7 cells produced cor- 
rectly cleaved Gly-extended gastrin with only a little ami- 
dated gastrin in the culture medium. 
2. Materials and methods 
2.1. Mutagenesis of human gastrin cDNA and construction of the 
expression vectors 
Human gastrin cDNA (Dr. E. Boel, Copenhagen, Denmark) [12] was 
modified to remove the 5’-poly(G) tail and the 3’-polyadenylation site, 
as described previously [13]. The DNA was subcloned into the BamHI 
site of a Ml3 mp19 RF form. All oligonucleotides were synthesized 
using an Applied Biosystems Model 391 PCR-Mate DNA Synthesizer. 
The mutant DNA was generated by using a site-directed in vitro mut- 
agenesis ystem kit (&kara, Kyoto, Japan). The progastrin sequence 
with or without mutation at the processing site was terminated after the 
Gly position of the G17-Gly. This truncation was carried out by insert- 
ing a stop codon after the Gly residue using a polymerase chain reaction 
(PCR) method [14]. An approximately 300 bp length of the truncated 
nroaastrin DNA was subcloned into the XhoI site of a pME18S expres- 
Siogvector (Dr. K. Maruyama, Institute of Medical Science, University 
of Tokyo). The promoter SRa of this vector is composed of the simian 
virus 40 early promoter, the R segment and part of the U5 sequence 
of the long terminal repeat of the human T-cell leukemia virus type I 
11% 
For amidating the C-terminal end of gas&in, we cloned a full se- 
ouence of PAM cDNA from a rat brain cDNA library using a partial 
EDNA clone for PAM (Dr. Betty A. Eipper, Johns Hopkins University, 
Baltimore) 1161. The full seauence of PAM cDNA was introduced into 
the EcoRI site of the pcDL-SRa vector equipped with a neomycin- 
resistant gene [15]. The two gastrin expression vectors, MGPl (with 
-Pro-Ser-Lys-‘-Lys-’ at the cleavage site), and MGP2 (with -Arg4- 
Arg-3-Lys-2-Arg-’ at the cleavage site) (Fig. lb), as well as the 
PAM expression vector, were purified twice by a cesium chloride gradi- 
ent centrifugation. 
2.2. Cell culture and DNA transfection by electroporation 
A Ham’s F12 medium, supplemented with 5% fetal bovine serum 
(FBS) (Gibco, Grand Island, NY), was used to culture the Chinese 
hamster ovary-derived CHO-K2 cells (ATCC CCL 61), and a Dul- 
bccco’s Modified Eagle’s medium (Sigma, St Louis, MO) with 10% FBS 
was used to culture the African green monkey kidney-derived COS-7 
cells (ATCC CRL 1651). Cells were placed in humidified, 5% CO2 at 
37’C. Transfection of DNA into the cells was carried out bv electrouo- 
ration using a Gene Pulser (Bio-Rad, Richmond, CA) as described 
before [17]. Twenty-four hours after the electroporation, the culture 
medium was harvested and the cells were incubated in a fresh medium 
for another 24 h. These COS-7 cells were used for the transient expres- 
sion of gastrin. The culture medium harvested after the second 24 h 
period was used for the analysis of immunoreactive gastrin (IRG). The 
CHO cells were made permanent by co-transfecting the MGPl or the 
MGP2 DNA construct with a plasmid containing a neomycin-resistant 
gene, and maintaining the culture in a medium containing the neomycin 
analogue G418 (0.4 mg/ml). The culture medium harvested after the 
first 24 h subculture was used to analyze the gastrin from the CHO cells. 
The medium was stored at -20°C for later analysis. 
The co-expression experiment was carried out using three different 
ratios of progastrin DNA to amidation enzyme cDNA (l:l/lO, 1: 113 
and 1:l). These were mixed maintaining the MGP2 DNA at 15 fig/ 
cuvette, and the electroporation was carried out in the same manner. 
2.3. Radioimmunoassay of amidated gastrin and glycine-extended 
gastrin 
G17-NH, (Peptide Institute, Osaka, Japan) was labeled with ‘*‘I 
using the standard lactoperoxidase method, and a carboxyterminal 
hexagastrin plus Gly peptide (GL7) [18] was labeled using the standard 
chloramine-T method. The radiolabeled peptides were purified using 
high performance liquid chromatography. Radioimmunoassay (RIA) 
fo; a&dated gastrin- was carried out using an antibody to G17-NH2 
(Ab 5135) (Dr. John H. Walsh. UCLA Medical School). This antibodv 
is specific’for gastrin-17 with an amide moiety at its C-terminal end [ 18j. 
The assay for Gly-extended gastrin was done using the antibody 
Ab8237, which is specific for gastrin-17 with a Gly moiety at its 
C-terminal end [18]. Standard assay mixtures consisted of the “‘I- 
peptide, various amounts of a standard peptide or unknown sample, 
and an appropriate antibody (final dilution of 1:90,000 for Ab5135, and 
1:30.000 for Ab8237) in 0.3 ml of 20 mM Tris-HCl buffer (nH 8.0) 
containing 0.2% egg albumin and 0.3% bovine y-globulin. Afteiincuba: 
tion for 1.5 h at 2O”C, 1 ml of 21% polyethylene glycol in 20 mM 
Tris-HCl buffer (pH 8.0) was added. After mixing the reaction solution, 
free and bound radioactivity was separated by centrifugation at 3,000 
rpm for 15 min, and the radioactivity was measured in a gamma 
counter. 
2.4. Geljiltration 
Gel filtration was performed with a 1.0 x 120 cm column (Bio-Rad) 
of a Sephadex G-SO-superfine gel (Pharmacia LKB, Piscataway, NJ) 
eauilibrated with a sodium barbital elution buffer (DH 8.6). Fractions 
of 1.5 ml were routinely collected. Size calibration w& carried out with 
blue dextran (Vo), potassium ferricyanide (Vt), and standard G17-NH2 
and G34-NH, (Peptide Institute). 
2.5. Amiaiztion enzyme assay 
The amidating activity of the cell lines was assayed by measuring the 
conversion of “‘I-labeled Ac-Tyr-Val-Gly to ‘251-labeled Ac-Tyr-Val- 
NH,. Ac-Tyr-Val-Gly (Peptide Institute) was radioiodinated by iodo- 
beads (Pierce, Rockford, IL). The standard assay protocol was as 
described by Mains et al. [19]. The enzyme source was untransfected 
cells which were scraped from the dish and suspended in 50 mM Tris- 
HCl (pH 7.0) with the protease inhibitor, aprotinin (100 units/ml). The 
protein content of the-cell extracts was measured with a micro-BCA 
nrotein assav kit (Pierce). The snecific activity of PAM was calculated 
by dividing-the PAM enzyme~activity by the protein content, and 
expressed as pmol/mg/h. 
2.6. RNA isolation and Northern blot analysis 
RNA was extracted and electrophoresed as described before [20]. 
Hybridization was performed with a probe of the amidation enzyme 
cDNA fragment (BamHI-PstI, 1.3 kb) labeled with [a-32P]dCTP. 
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3. Results 
3.1. Construction of gastrin expression vectors 
We mutated a native gastrin cDNA (Fig. la) to replace 
the original cleavage site, -Pro-4-Ser-3-Lys-2-Lys-1, with 
a new cleavage site, -Arg-4-Arg-3-Lys-2-Argrg-‘. Then, to 
simplify the processing reaction, we truncated the 
C-terminal extension region of progastrin by inserting a 
stop codon just after G17-Gly (Fig. lb). With Gly as the 
C-terminus, the truncated precursor will serve as a direct 
substrate for PAM without any cleavage reaction. The 
truncated gastrin precursor with the original cleavage 
site is named MGPl, the precursor with the new cleavage 
site is named MGP2 (Fig. lb). Both precursor cDNAs 
were inserted into the mammalian expression vector 
pME18S. 
3.2. Amidating activity and RNA analysis 
We chose the two cell lines, CHO and COS-7 for this 
study. Johansen et al. found that CHO amidates ex- 
ogenously expressed neuropeptide Y (NPY) [lo], and 
Eipper et al. found that COS-7 contains the PAM 
mRNA [l 11. Fig. 2a shows that the CHO cells exhibit 
enzyme activity comparable to the PAM activity of the 
rat pituitary endocrine cell line, GH3, whereas the en- 
zyme activity of the COS-7 cells is much lower. 
Northern blots probed with the cDNA for PAM re- 
vealed a prominent band of hybridization with RNA 
from CHO cells, but only a barely visible band with that 
from COS-7 cells (Fig. 2b). The density of the hybridiza- 
tion band of the RNA from CHO is less than half of that 
from GH, cells, and did not reflect the comparable en- 
zyme activities between CHO and GH3 cells. Anyway, 
the content of PAM enzyme activity and the presence of 
RNA in the COS-7 and CHO cells is in marked contrast. 
3.3. Expression of gastrin 
Both CHO and COS-7 cells transfected with MGPl or 
MGP2 DNA produced a substantial amount of gastrin 
products. As expected, the cells retained only 1 to 3% of 
the gastrin released into the culture medium. The same 
result has been observed in other non-endocrine cell 
lines: NIH3T3 cells, baby hamster kidney-derived fi- 
broblast-like BHK cells, and rat hepatoma-derived 
Hepald cells [21]. The characteristics of gastrin prod- 
ucts were monitored by two antibodies: C-terminal 
glycine-specific (Ab8237), and C-terminal amide-specific 
(Ab5135) [18]. 
When either MGPl or MGP2 was expressed in CHO 
cells, a substantial amount of amidated gastrin was pro- 
duced in the culture medium but only a trace of Gly- 
extended gastrin was produced (Table 1). The ratio of 
amidated gastrin to the total of Gly-extended gastrin 
plus amidated gastrin is almost 99% in both the MGPi 
and MGPZexpressing CHO cell lines. This result is con- 
sistent with the data by Johansen et al., which demon- 
strated that CHO transfected with a NPY cDNA pro- 
duced mostly amidated NPY in the culture medium [lo]. 
In contrast, when MGPl and MGP2 were expressed in 
COS-7 cells, Gly-extended gastrin was produced much 
more abundantly than amidated gastrin (Table 1). The 
ratio of amidated gastrin to the total of Gly-extended 
plus amidated gastrins was 27% in MGPl-expressing 
COS-7 cells and 12% in MGPZexpressing COS-7 cells. 
a) Native gastrin precursor 
b) Mutant gastrin precursors 
MOP2 ~-I’WJQ~.Q@QL~~A~~ GUY 
Furin 
Amldatlon enzyme 
NHz 
Fig. 1. Structures of gastrin precursor constructs. (a) Structure of a native gastrin precursor (NGP). The 101 amino acid human gastrin precursor 
is shown with the signal peptide and three dibasic cleavage sites Args7-A$*, Ly~‘~-Lys”, Arp-A$‘. The amino acid is numbered from the methionin 
residue at the amino terminus of the gastrin precursor. The cleavage of these dibasic residues leads to the formation of G17-NH, and G34-NH,, which 
are underlined with a solid bar. (b) Structures of the truncated gastrin precursor with an original cleavage site, Lys-‘-Lys-’ (MGPl), and a tetrabasic 
cleavage site, Arg-4-Arg-3-Lys%4rgrg-’ (MGP2). This amino acid is numbered from the last basic residue at the cleavage site. Both MGPl and MGP2 
have a glycine residue at the C-terminal end. 
30 
cos-7 CHO GH3 
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Fig. 2. Analysis of the amidation enzyme PAM in COS-7, CHO, and GH, cells. (a) Amidating enzyme activity in cultured cell lines in vitro. The 
assay was carried out at least three times for each cell line. The values are expressed as the mean f SE. (b) Northern blot analysis of each cell line 
with a probe for PAM. Ribosomal RNA size markers electrophoresed on the same gel are indicated as 28s and 18S. The size of PAM RNA in each 
cell line was estimated to be approximately 4.0 kb. 
3.4. Gel filtration 
We further characterized the molecular size of the gas- 
trim produced from the CHO and COS-7 cells using 
Sephadex G-50 superfine columns. The amidated gastrin 
products from the MGPl-expressing CHO cells were 
separated into two dominant sizes, shown as a large and 
a small peak (Fig. 3, left upper panel). The small peak 
corresponded to the G17-NH, standard. The large peak 
eluted just before the G34-NH, position. The im- 
munoreactive gas&in (IRG) from the MGPZexpressing 
CHO cells also showed two peaks, but in this case the 
second peak (corresponding to the G17-NH2 standard) 
was larger than the first (Fig. 3, left lower panel). Thus, 
the MGP2 gastrin precursor was cleaved much more 
efficiently than the MGPl precursor by endogenous en- 
doproteases. 
Since the gastrin products from COS-7 cells are mostly 
Gly-extended gastrin with some of amidated gastrin, we 
analyzed the size of the Gly-extended gastrin. The gastrin 
products from the MGPl -expressing COS-7 cells showed 
two dominant molecular sizes, as did those from the 
CHO cells (Fig. 3, right upper panel). As from the CHO 
cells, the first large peak corresponded to molecules 
Table 1 
Production of Gly-extended and amidated gastrin in the MGPl and 
MGPZ-expressing COS-7 and CHO cells 
Cell type Transfected Gly-extended Amidated 
DNA gastrin gastrin 
(fmol/mY (fmol/ml/ 
lo6 cells) lo6 cells) 
cos-7 MGPl 712.5 f 165.8 257.1 f 32.5 
MGP2 1,285.8 f 483.7 176.2 f 12.4 
CHO MGPl 6.0 f 6.0 698.4 + 133.9 
MGP2 5.8 f 5.0 488.0 f 71.3 
Values are expressed as mean + SE. 
slightly larger than the G34-NH* standard, and the sec- 
ond peak corresponded to the G17-NH2 standard. The 
MGPZexpressing COS-7 cells produced only a single 
peak, corresponding to the G17-NH, standard (Fig. 3, 
right lower panel). Thus, the cleavage of the mutated 
progastrin MGP2 is more efficient in COS-7 cells than 
in CHO cells. 
3.5. Co-expression of gastrin with PAM in COS-7 cells 
To obtain more amidated gastrin from the COS-7 
CHO cos-7 
Fraction number 
Fig. 3. Gel filtration of IRG in media from CHO and COS-7 cells 
transformed to express MGPl and MGP2 DNA. (a) MGPl-expressing 
CHO cells; (b) MGP2-expressing CHO cells; (c) MGPl-expressing 
COS-7 cells; (d) MGP2-expressing COS-7 cells. IRG in eluted fractions 
was analyzed with the Ab5135 antibody (0) and Ab8237 antibody (o), 
as described in Section 2. Columns were calibrated with blue dextran 
(Vo), potassium ferricyanide (Vt), and standard Gl7-NH* and G34- 
NH2. Similar chromatograms were obtained in at least three other 
experiments for each cell line. 
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3 5 15 
PAM cDNA (pg) 
Fig. 4. The relative ratio of Gly-extended gastrin and amidated gastrin 
in the co-expression of MGP2 and PAM in COS-7 cells. 15 ,ug of MGP2 
DNA was co-transfected to COS-7 cells with three different amounts 
of PAM cDNA (1.5 pg, 5.0 ,ug, and 15 pg). IRG was assayed with the 
antibodies Ab5135 and Abg237 as described in Section 2. The amount 
of each gastrin form is expressed as the percentage of the total gastrin 
(Gly-extended gastrin plus amidated gastrin). The hatched column rep- 
resents the percentage of amidated gastrin, and the open column does 
that of Gly-extended gastrin. 
cells, we co-expressed the amidation enzyme cDNA to- 
gether with the MGP2 DNA. The PAM cDNA-trans- 
fected COS-7 cells showed amidating enzyme activity as 
high as that of CHO cells. As expected, increased 
amounts of PAM cDNA caused increased amounts of 
amidated gastrin products, and correspondingly de- 
creased amounts of Gly-extended gastrin (Fig. 4). Gly- 
extended gastrin must be utilized as a substrate for the 
amidation reaction. 
4. Discussion 
In this study we have shown that non-endocrine cells 
are able to produce correctly cleaved and amidated gas- 
trin if the gastrin precursor is designed to undergo cleav- 
age by the non-endocrine cell-specific endoprotease 
furin. The need for the expression of the amidation en- 
zyme, PAM, depends on the level of the endogenous 
amidation enzyme activity in the non-endocrine cells. 
It has been long understood that propeptide-express- 
ing non-endocrine cells produce only non-processed 
propeptides, as demonstrated in a variety of non-endo- 
crine cell lines, such as CHO, COS, and NIH3T3 [21-231. 
However, in exceptional cases, some peptide precursors 
were correctly cleaved in non-endocrine cells. Warren 
and Shields [24] observed correctly cleaved somatostatin 
in non-endocrine cell line COS-7, as did Sevarino et al. 
[25] in the non-endocrine cell line 3T3-Swiss-Albino. In 
both cases, however, the cleaved fraction was small com- 
pared to the uncleaved somatostatin precursor. More 
recently, partial cleavage of the NPY precursor was re- 
ported in transfected CHO cells [26]. Partial cleavage was 
also observed in the pancreatic polypeptide (PP) precur- 
sor, a peptide hormone of the same family, by expressing 
its cDNA in NIH3T3, Hepald, and BHK cells [21]. The 
cleavage of certain propeptide hormones is explained by 
the resemblance of processing sites of a precursor to the 
concensus processing sequence of non-endocrine cells, 
-Arg-4-X-3-Lys/Arg-2-Arg-‘. The order of the basic 
amino acids in their cleavage sites, however, does not 
strictly adhere to this rule. This type of cleavage is useful 
for producing small, bioactive peptide hormones from 
non-endocrine cells [ 17,201. 
One unexpected result was the appearance of an IRG 
peak close to the standard G34-NH* position. In the 
previous study [21], when the full sequence of native 
progastrin was expressed in non-endocrine cells 
(NIH3T3 derived-psi2, BHK, and Hepal-6) the only 
large IRG peak appeared close to the void volume on a 
Sephadex G-50 gel filtration using an antibody that rec- 
ognizes the arginin-extended progastrin, but not recog- 
nizes the glycine-extended or amidated gastrin. Since 
IRG was not examined with antibodies reactive to the 
glycine-extended or amidated gastrin, we did not know 
of the IRG peak close to the G34-NH, position in that 
study [21]. 
Amidation is the other important reaction for the 
processing of most peptide hormones to induce their full 
biological potency [3,4]. When peptide hormone precur- 
sors are expressed in endocrine cell lines such as GH, 
cells, mouse pituitary-derived AtT20 cells, rat insuli- 
noma-derived RIN cells, or rat pheochromocytoma- 
derived PC12 cells, they are correctly cleaved and ami- 
dated [27]. In contrast to the processing in endocrine 
cells, the peptide hormone precursors in non-endocrine 
cells are not generally cleaved and the C-terminal glycine 
is not exposed for the amidation reaction [21]. Thus, the 
amidation capability in non-endocrine cells remained to 
be investigated. Recently, Johansen et al. demonstrated 
that 50 to 80% of the exogenously expressed NPY was 
amidated in CHO cells by using an antibody specific for 
the C-terminal amide moiety of NPY [lo]. Dickinson et 
al. also demonstrated efinite amidation of exogenously 
expressed PP in an exocrine pancreatic cell line, AR42J, 
which contains high levels of amidation enzyme mRNA 
comparable to that in CHO and GH, cells [21]. Thus, the 
amidation capability of non-endocrine cells appears to 
depend on the amidation enzyme activity of non-endo- 
crine cell lines. This was exemplified by our present data 
using the two cell lines, CHO and COS-7, which had 
contrasting amounts of amidation enzyme. CHO essen- 
tially produced only amidated gastrin while COS-7 pro- 
duced mostly non-amidated Gly-extended gastrin. Thus, 
in order to produce amidated, bioactive gastrin from 
cells with low amidating activity, co-expression of PAM 
is required. 
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